The use of tacrolimus as induction and maintenance immunosuppression in renal cadaveric transplant recipients over the age of 60

Eleftherios X. Xenos, Gaetano Ciancio, George W. Burke, David Roth, Joshua Miller

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Renal transplantation is a treatment option that should be considered for the elderly ( ≤ 60 years old) with end-stage renal disease. Little is known regarding the use of tacrolimus (as induction and maintenance immunosuppression) in this age group. We report the outcome of kidney transplantation in 21 patients aged 60 years or more with tacrolimus. During the past few years in kidney transplant maintenance immunosuppressive regimens, we have revised our standard general protocol from cyclosporine to tacrolimus-based therapy for maintenance immunosuppression and for rescue therapy. We also introduced mycophenolate (RS-61443) while we have continued to use ATGAM/OKT3 as induction regimen in the immediate postoperative period. We treated these renal recipients with tacrolimus and steroids in combination with azathioprine or mycophenolate mofetil without antibody induction. This was well tolerated and not associated with a higher rate of rejection (20%) whereas the potential toxicity of antilymphocyte preparations was avoided.

Original languageEnglish
Pages (from-to)497-499
Number of pages3
JournalClinical Transplantation
Volume11
Issue number5 II
StatePublished - Oct 1 1997

Fingerprint

Tacrolimus
Immunosuppression
Maintenance
Mycophenolic Acid
Kidney
Kidney Transplantation
Muromonab-CD3
Antilymphocyte Serum
Azathioprine
Immunosuppressive Agents
Postoperative Period
Cyclosporine
Chronic Kidney Failure
Therapeutics
Age Groups
Steroids
Transplants
Transplant Recipients
Antibodies

Keywords

  • Age
  • Renal transplantation
  • Tacrolimus

ASJC Scopus subject areas

  • Transplantation
  • Immunology

Cite this

The use of tacrolimus as induction and maintenance immunosuppression in renal cadaveric transplant recipients over the age of 60. / Xenos, Eleftherios X.; Ciancio, Gaetano; Burke, George W.; Roth, David; Miller, Joshua.

In: Clinical Transplantation, Vol. 11, No. 5 II, 01.10.1997, p. 497-499.

Research output: Contribution to journalArticle

@article{f17e9a9628c74eb0a67d08d13557578d,
title = "The use of tacrolimus as induction and maintenance immunosuppression in renal cadaveric transplant recipients over the age of 60",
abstract = "Renal transplantation is a treatment option that should be considered for the elderly ( ≤ 60 years old) with end-stage renal disease. Little is known regarding the use of tacrolimus (as induction and maintenance immunosuppression) in this age group. We report the outcome of kidney transplantation in 21 patients aged 60 years or more with tacrolimus. During the past few years in kidney transplant maintenance immunosuppressive regimens, we have revised our standard general protocol from cyclosporine to tacrolimus-based therapy for maintenance immunosuppression and for rescue therapy. We also introduced mycophenolate (RS-61443) while we have continued to use ATGAM/OKT3 as induction regimen in the immediate postoperative period. We treated these renal recipients with tacrolimus and steroids in combination with azathioprine or mycophenolate mofetil without antibody induction. This was well tolerated and not associated with a higher rate of rejection (20{\%}) whereas the potential toxicity of antilymphocyte preparations was avoided.",
keywords = "Age, Renal transplantation, Tacrolimus",
author = "Xenos, {Eleftherios X.} and Gaetano Ciancio and Burke, {George W.} and David Roth and Joshua Miller",
year = "1997",
month = "10",
day = "1",
language = "English",
volume = "11",
pages = "497--499",
journal = "Clinical Transplantation",
issn = "0902-0063",
publisher = "Wiley-Blackwell",
number = "5 II",

}

TY - JOUR

T1 - The use of tacrolimus as induction and maintenance immunosuppression in renal cadaveric transplant recipients over the age of 60

AU - Xenos, Eleftherios X.

AU - Ciancio, Gaetano

AU - Burke, George W.

AU - Roth, David

AU - Miller, Joshua

PY - 1997/10/1

Y1 - 1997/10/1

N2 - Renal transplantation is a treatment option that should be considered for the elderly ( ≤ 60 years old) with end-stage renal disease. Little is known regarding the use of tacrolimus (as induction and maintenance immunosuppression) in this age group. We report the outcome of kidney transplantation in 21 patients aged 60 years or more with tacrolimus. During the past few years in kidney transplant maintenance immunosuppressive regimens, we have revised our standard general protocol from cyclosporine to tacrolimus-based therapy for maintenance immunosuppression and for rescue therapy. We also introduced mycophenolate (RS-61443) while we have continued to use ATGAM/OKT3 as induction regimen in the immediate postoperative period. We treated these renal recipients with tacrolimus and steroids in combination with azathioprine or mycophenolate mofetil without antibody induction. This was well tolerated and not associated with a higher rate of rejection (20%) whereas the potential toxicity of antilymphocyte preparations was avoided.

AB - Renal transplantation is a treatment option that should be considered for the elderly ( ≤ 60 years old) with end-stage renal disease. Little is known regarding the use of tacrolimus (as induction and maintenance immunosuppression) in this age group. We report the outcome of kidney transplantation in 21 patients aged 60 years or more with tacrolimus. During the past few years in kidney transplant maintenance immunosuppressive regimens, we have revised our standard general protocol from cyclosporine to tacrolimus-based therapy for maintenance immunosuppression and for rescue therapy. We also introduced mycophenolate (RS-61443) while we have continued to use ATGAM/OKT3 as induction regimen in the immediate postoperative period. We treated these renal recipients with tacrolimus and steroids in combination with azathioprine or mycophenolate mofetil without antibody induction. This was well tolerated and not associated with a higher rate of rejection (20%) whereas the potential toxicity of antilymphocyte preparations was avoided.

KW - Age

KW - Renal transplantation

KW - Tacrolimus

UR - http://www.scopus.com/inward/record.url?scp=0030810332&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030810332&partnerID=8YFLogxK

M3 - Article

C2 - 9361949

AN - SCOPUS:0030810332

VL - 11

SP - 497

EP - 499

JO - Clinical Transplantation

JF - Clinical Transplantation

SN - 0902-0063

IS - 5 II

ER -